Initial indications of this collaborative research agreement will focus on how to use knowledge of T-cell signaling pathways to design novel cancer therapeutics and broaden to other indications over time. Lentigen will be granted exclusive rights to commercialize resulting products.
“This collaboration will permit the large-scale experiments that are required to move an idea from the bench to the bedside,” said Dr James Riley, an associate professor of pathology and laboratory medicine at the University of Pennsylvania.
No financial terms of the agreement have been disclosed.